欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (3): 306-311.doi: 10.12092/j.issn.1009-2501.2020.03.010

• 临床药理学 • 上一篇    下一篇

阿哌沙班片在中国健康志愿者体内的生物等效性研究

宁晓艺,况 赟,黄 洁,刘亚男,阳晓燕,杨 双,郭 灿,阳国平   

  1. 中南大学湘雅三医院临床药理中心,长沙 410013,湖南
  • 收稿日期:2019-12-23 修回日期:2020-02-26 出版日期:2020-03-26 发布日期:2020-04-13
  • 通讯作者: 阳国平,男,博士,教授,博士生导师,主要从事临床药理学方向研究。 Tel: 0731-89918665 E-mail: ygp9880@126.com
  • 作者简介:宁晓艺,女,在读硕士生,主要从事临床药理学方向研究。 Tel: 15675899402 E-mail: ningxiaoyi1996@163.com
  • 基金资助:
    国家自然科学基金(81673519);中国国际科技合作计划(2014DFA30900)

Bioequivalence of apixaban tablets in healthy Chinese subjects

NING Xiaoyi, KUANG Yun, HUANG Jie, LIU Yanan, YANG Xiaoyan, YANG Shuang, GUO Can, YANG Guoping   

  1. Center of Clinical Pharmacology, the Third Xiangya Hospital of Central South University, Changsha 410013, Hunan, China
  • Received:2019-12-23 Revised:2020-02-26 Online:2020-03-26 Published:2020-04-13

摘要: 目的:评价空腹及餐后单次口服阿哌沙班受试制剂和参比制剂的生物等效性。方法:采用单中心、随机设计,空腹组和餐后组受试者各24例,每周期口服受试制剂或参比制剂2.5 mg。采用LC-MS/MS法测定阿哌沙班血药浓度。采用WinNonlin6.4软件计算药动学参数,并进行生物等效性评价。结果:空腹组受试制剂与参比制剂的药动学参数分别为:Cmax(80±14)和(87±21) ng/mL,AUC0-t(713±136)和(733±142) h·ng·mL-1,AUC0-∞(722±143)和(741±142) h·ng·mL-1,tmax 2.5 h和2.5 h,t1/2(9±8)和(8±6) h,相对生物利用度按AUC0-t计算为97.16%,按AUC0-∞计算为97.20%。餐后组受试制剂与参比制剂的药动学参数分别为:Cmax(70±13)和(72±13) ng/mL,AUC0-t(642±130)和(690±135) h·ng·mL-1,AUC0-∞(652±129)和(704±138) h·ng·mL-1,tmax 2.5 h和2.5 h,t1/2(8±4)和(12±9) h,相对生物利用度按AUC0-t计算为93.03%,按AUC0-∞计算为92.62%。结论:受试制剂和参比制剂的空腹和餐后用药生物等效。

关键词: 阿哌沙班, LC/MS-MS, 生物等效性, 药代动力学

Abstract: AIM: To evaluate the bioequivalence of the two preparations of apixaban tablets administered once orally under fasting and fed conditions. METHODS: The study was designed as randomized, open, self-crossover, and twenty four healthy volunteers were recruited respectively in fasting and fed conditions. Subjects were assigned to receive a single oral of the test or reference formulation per period at a dose of 2.5 mg. The plasma apixaban concentration was analyzed by LC-MS/MS. The major pharmacokinetic parameters were calculated by WinNonlin 6.4 and the bioequivalence was evaluated.RESULTS:The main pharmacokinetic parameters of a single oral apixaban under fasting condition for T and R were as follows: Cmax (80±14) and (87±21) ng/mL, AUC0-t (713±136) and (733±142) h·ng·mL-1, AUC0-∞ (722±143) and (741±142) h·ng·mL-1, tmax 2.5 h and 2.5 h, t1/2 (9±8) and (8±6) h. The relative bioavailability was 97.16% for AUC0-t, 97.20% for AUC0-∞. The main pharmacokinetic parameters of a single oral apixaban under fed condition for T and R were as follows: Cmax (70±13), (72±13) ng/mL; AUC0-t (642±130), (690±135) h·ng·mL-1; AUC0-∞ (652±129), (704±138) h·ng·mL-1. tmax 2.5 h and 2.5 h, t1/2 (8±4) and (12±9) h. The relative bioavailability was 93.03% for AUC0-t, 92.62% for AUC0-∞. CONCLUSION: The test preparation of apixaban tablets is bioequivalent to the reference preparation under both fasting and fed conditions.

Key words: apixaban, LC/MS-MS, bioequivalence, pharmacokinetics

中图分类号: